Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Hans M.G. Princen"'
Autor:
Elsbet J. Pieterman, Marianne G. Pouwer, Lori L. Jennings, Alain J. van Gool, Jan H.N. Lindeman, Maarten D. Sollewijn Gelpke, Danielle van Keulen, Hans M.G. Princen, Vilmundur Gudnason, Valur Emilsson, Gerard Pasterkamp, Kim Holmstrøm, Ljubica Perisic Matic, Boye Schnack Nielsen, Dennie Tempel, Ulf Hedin
Publikováno v:
PLoS ONE, 14(8). Public Library of Science
Plos One, 8, 14, e0221477
PLoS ONE
PLoS ONE, 14(8). PUBLIC LIBRARY SCIENCE
PLoS ONE, Vol 14, Iss 8, p e0221477 (2019)
Plos One, 8, 14, e0221477
PLoS ONE
PLoS ONE, 14(8). PUBLIC LIBRARY SCIENCE
PLoS ONE, Vol 14, Iss 8, p e0221477 (2019)
ObjectivePrevious studies indicate a role for Oncostatin M (OSM) in atherosclerosis and other chronic inflammatory diseases for which inhibitory antibodies are in development. However, to date no intervention studies with OSM have been performed, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9390ed769904473deef47d2afd5dee3
https://dspace.library.uu.nl/handle/1874/390802
https://dspace.library.uu.nl/handle/1874/390802
Autor:
Christian Werner, Susanne Schuster, Sandra Rubil, Matthias Endres, Karsten Winter, Ulrich Laufs, J.-N Boeckel, Hans M.G. Princen
Publikováno v:
Scientific reports 9(1), 11079 (2019). doi:10.1038/s41598-019-47242-0
Scientific Reports, 1, 9
Scientific Reports, Vol 9, Iss 1, Pp 1-8 (2019)
Scientific Reports
Scientific Reports, 1, 9
Scientific Reports, Vol 9, Iss 1, Pp 1-8 (2019)
Scientific Reports
LDL-cholesterol (LDL-C) is a causal pathogenic factor in atherosclerosis. Monoclonal anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) neutralizing antibodies are novel potent LDL-lowering drugs which reduce cardiovascular events. To charact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acb54ae668afdb61322526b07e37960e
Autor:
Joyce Chi Yee Chan, Simon Jackson, Hans M.G. Princen, José W.A. van der Hoorn, Scott M. Wasserman, Elsbet J. Pieterman, Brandon Ason, Kathy Nguyen, Susan Shetterly, Mei Di, Margrit Schwarz, J. Wouter Jukema, Jie Tang, Edward Lee, Rob Scott, Wen-Chen Yeh
Publikováno v:
Journal of Lipid Research, 55(11), 2370-2379
Journal of Lipid Research, Vol 55, Iss 11, Pp 2370-2379 (2014)
Journal of Lipid Research, 11, 55, 2370-2379
Journal of Lipid Research, Vol 55, Iss 11, Pp 2370-2379 (2014)
Journal of Lipid Research, 11, 55, 2370-2379
LDL cholesterol (LDL-C) contributes to coronary heart disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases LDL-C by inhibiting LDL-C clearance. The therapeutic potential for PCSK9 inhibitors is highlighted by the fact that PCSK9 l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a39084ecc72a660fcf4dd482ee87539a
https://hdl.handle.net/1887/103264
https://hdl.handle.net/1887/103264
Autor:
Gene Liau, Hans M.G. Princen, José W.A. van der Hoorn, Anita M. van den Hoek, J. Wouter Jukema, Louis M. Havekes, Susan Kühnast
Publikováno v:
Journal of Hypertension, 1, 30, 107-116
Journal of Hypertension, 30(1), 107-116
Journal of Hypertension, 30(1), 107-16
Journal of Hypertension, 30(1), 107-116
Journal of Hypertension, 30(1), 107-16
Objective: Aliskiren is the first commercially available, orally active, direct renin inhibitor approved to treat hypertension. The renin-angiotensin system has been shown to be a significant contributor to the development of hypercholesterolemia-ind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcbe2be8b56e63327af1e3e80f95671b
https://hdl.handle.net/1887/111167
https://hdl.handle.net/1887/111167